deltatrials
Suspended PHASE3 NCT00002696

Combination Chemotherapy in Treating Women With Stage III Breast Cancer

MULTIMODALITY TREATMENT STRATEGY FOR STAGE III BREAST CANCER

Sponsor: Grupo Oncologico Cooperativo del Sur

Conditions Breast Cancer
Interventions CAF regimen CMF regimen adjuvant therapy conventional surgery cyclophosphamide doxorubicin hydrochloride fluorouracil methotrexate neoadjuvant therapy radiation therapy
Updated 6 times since 2017 Last updated: Aug 1, 2013 Started: Oct 31, 1995

Listed as NCT00002696, this PHASE3 trial focuses on Breast Cancer and remains suspended. Sponsored by Grupo Oncologico Cooperativo del Sur, it has been updated 6 times since 1995, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Suspended PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Suspended PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Suspended PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Suspended PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Suspended PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Suspended PHASE3

    First recorded

Oct 1995

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Grupo Oncologico Cooperativo del Sur
Data source: National Cancer Institute (NCI)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Bahía Blanca, Argentina
  • • Mar del Plata, Argentina
  • • Neuquén, Argentina
  • • Río Gallegos, Argentina
  • • Santa Fe, Argentina
  • • Santa Rosa, Argentina
  • • Tres Arroyos, Argentina